Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Treasury Shares (2016 - 2025)

Oramed Pharmaceuticals filings provide 11 years of Treasury Shares readings, the most recent being $4.4 million for Q4 2025.

  • Quarterly Treasury Shares rose 70.43% to $4.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.4 million through Dec 2025, up 70.43% year-over-year, with the annual reading at $4.4 million for FY2025, 70.43% up from the prior year.
  • Treasury Shares hit $4.4 million in Q4 2025 for Oramed Pharmaceuticals, up from $3.1 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $4.5 million in Q2 2022 and bottomed at $118522.0 in Q2 2024.
  • Average Treasury Shares over 5 years is $2.2 million, with a median of $1.8 million recorded in 2023.
  • The largest annual shift saw Treasury Shares grew 17.47% in 2023 before it surged 480.22% in 2025.
  • Oramed Pharmaceuticals' Treasury Shares stood at $921302.0 in 2021, then surged by 69.5% to $1.6 million in 2022, then increased by 17.47% to $1.8 million in 2023, then soared by 40.22% to $2.6 million in 2024, then skyrocketed by 70.43% to $4.4 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Treasury Shares are $4.4 million (Q4 2025), $3.1 million (Q3 2025), and $2.6 million (Q4 2024).